Similar trends for most oxylipins derived from AA have been described comparing NAFLD subjects to healthy controls [52] and in NASH patients compared to NAFLD patients [7,28], evidencing the associations between the activation of LOX pathways and the progression of the disease to NASH. Here, LOX is linked to metabolic dysfunction-associated steatotic liver disease.